Novel immunotherapy in metastatic renal cell carcinoma

Despite the rapid development of therapeutic modalities for metastatic renal cell carcinoma (mRCC) over the past decade to include a number of targeted antiangiogenic therapies and traditional immunotherapy, such as high-dose interleukin-2 and interferon-α, mRCC continues to be associated with poor...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Yang Hyun, Kim, Myung Soo, Chung, Ho Seok, Hwang, Eu Chang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Urological Association 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494344/
https://www.ncbi.nlm.nih.gov/pubmed/28681030
http://dx.doi.org/10.4111/icu.2017.58.4.220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494344/
https://www.ncbi.nlm.nih.gov/pubmed/28681030
http://dx.doi.org/10.4111/icu.2017.58.4.220

Ejemplares similares